BofA turns bearish on Salix Pharma

BofA cuts Salix Pharmaceuticals (SLXP) to Underperform from Neutral.

This is a valuation call. Here's analyst Gregg Gilbert: "With the stock now trading above our PO, which we believe reflects a relatively bullish set of assumptions, we are moving to an Underperform rating."

The bullish assumptions: "Stronger performance for the base business, more credit for the late-stage pipeline, and significant contribution from the Santarus acquisition."

$86 target maintained.

SLXP -1.7% premarket

From other sites
Comments (3)
  • jurpsy
    , contributor
    Comments (6) | Send Message
    What 's the value & future of Ruconest in this acquisition?
    Nobody speaks about it...
    Any idea?.
    7 Jan 2014, 11:29 AM Reply Like
  • Bronxstu
    , contributor
    Comments (117) | Send Message
    Interesting, Stifel gives a buy rating with a price target of 108 on Dec 17. Time will tell
    7 Jan 2014, 01:05 PM Reply Like
  • jurpsy
    , contributor
    Comments (6) | Send Message
    I asked Salix twice the same questions, just until now, silence is the answer....
    7 Jan 2014, 03:35 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs